June 1st 2023
Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our May 2023 month in review features new FDA approvals, important phase 2 data, and in-depth clinician perspective.
Phase 2b Trial Suggests Efficacy of Oral Danuglipron for Glycemic Control in T2DMay 24th 2023
Phase 2 data suggest the oral small-molecule GLP-1R agonist reduced HbA1c at all dose levels studied and reduced body weight at doses of ≥80 mg twice daily compared with placebo in adults with T2D.
Higher Prevalence of Diabetic Retinopathy Observed in Patients with T2D, Diabetic NephropathyMay 11th 2023
Logistic regression analysis indicated that higher stages of urine albumin creatine ratio were significantly associated with diabetic retinopathy in patients with T2D and diabetic nephropathy.
Contemporary Study Data Offer Overview of Challenges, Outcomes for Adolescents with T1D, T2DMay 9th 2023
Pooling data from the TODAY and SEARCH studies, new research offers an overview of the challenges in access to care and outcomes among adolescents with type 1 and type 2 diabetes
Hour-Long Endoscopic Procedure Could Eliminate Need for Insulin in Type 2 DiabetesMay 4th 2023
New research from a first-in-human study of a novel procedure involving electroporation of the superficial layer of the mucosa in the small intestine could help eliminate need for insulin in some people with type 2 diabetes.
Endocrinology Month in Review: April 2023May 2nd 2023
Each month, our editorial staff compiles a recap of the top news in endocrinology from the past month. Our April 2023 month in review features top new studies, FDA approvals, and an overview of news surrounding Abbott readers.
Tirzepatide Achieves Mean Weight Loss of 15.7% in SURMOUNT-2 TrialApril 27th 2023
Data from the SURMOUNT-2 trial demonstrate use of tirzepatide 10 mg and 15 mg were associated with mean weight reductions of 13.4% and 15.7%, respectively, with more than 80% of tirzepatide users achieving a body weight reduction of 5% or greater.
Omnipod GO Receives FDA Clearance for People with Type 2 DiabetesApril 25th 2023
Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.
Healthy Beverage Choices May Lower Mortality Risk in Adults with DiabetesApril 20th 2023
An analysis of adults with T2D found a higher intake of sugar-sweetened beverages was associated with higher all-cause mortality and CVD incidence, whereas healthier beverage options were inversely associated with all-cause mortality.
US Prisoners Being Undertreated for Common Chronic Health ConditionsApril 17th 2023
A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.
Study: Insulin Shelf Life Could Be 4 Times Longer than Previously ReportedApril 12th 2023
A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.
FDA Issues Class I Recall of Abbott FreeStyle Readers for Risk of Overheating, FireApril 6th 2023
Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.
Transcatheter Arterialization Could Revolutionize Treatment of Limb-Threatening IschemiaMarch 31st 2023
Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.
10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic CareMarch 29th 2023
This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.
Endocrine Case Report: Ear Pain in DiabetesMarch 27th 2023
Our latest endocrine case report from Brady Pregerson, MD, features a patient in their mid-70s with a history of diabetes mellitus and end-stage kidney disease presenting with 6 days of gradually worsening right ear pain. Can you determine the correct diagnosis?
Metformin Could Lower Osteoarthritis Risk in Type 2 DiabetesMarch 26th 2023
A retrospective analysis comparing propensity score matched metformin users against sulfonylurea users, results of the study indicate metformin use was associated with a 24% reduction in relative risk of developing osteoarthritis.